Dennis Purcell

Dennis Joseph Purcell is the founder of Aisling Capital LLC, serving as Senior Advisor since 1998.
Current jobs include Chairman at Solvonis Therapeutics Plc since 2024, Director at Rosetta Capital Ltd. since 2017, Director at Real Endpoints LLC, Independent Director and Advisor at Bioscience Managers Pty Ltd. since 2003, Chief Operating Officer & Director at Summus Global, Inc., Non-Executive Director at Ichnos Glenmark Innovation, Inc., Director at ViralClear Pharmaceuticals, Inc. since 2020, and Advisor at The New York City Investment Fund Manager, Inc. Former jobs include Special Advisor to the CEO at Awakn Life Sciences Corp., Executive Chairman at Poliwogg Holdings, Inc., Director at Valentis, Inc., Director at Paratek Pharmaceuticals, Inc. from 2009 to 2012, Director at Cengent Therapeutics, Inc., Director at Bridge Pharmaceuticals, Inc., Director at Biotechnology Innovation Organization, Director at Embera NeuroTherapeutics, Inc., Director at Dynova Laboratories, Inc., Managing Director at PaineWebber, Inc., Director at Aton Pharma, Inc., Managing Director at Chase H&Q from 1995 to 1998, Director at Xanodyne Pharmaceuticals, Inc., Director at New York Biotechnology Association, Inc., Director at The Irvington Institute for Immunological Research, and Member at Harvard Medical School.
Education includes an MBA from Harvard University and an undergraduate degree from the University of Delaware.